New approaches in the treatment of hepatitis C

doi:10.3748/wjg.v22.i4.1421

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 22, Issue 4

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (15263)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-4) series.

Item

Count

PDF

1492

WORD

369

HTML

9540

Tables (1-4)

122

Sum=11523

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

362

Download

698

Sum=1060

Publishing Process of This Article

Item

Count

Browse

1199

Download

1481

Sum=2680

Jan 28, 2016 (publication date) through Apr 23, 2024

Times Cited of This Article

Times Cited (102)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Topic Highlight

World J Gastroenterol. Jan 28, 2016; 22(4): 1421-1432
Published online Jan 28, 2016. doi: 10.3748/wjg.v22.i4.1421

Table 1 Recommendations for therapy in patients with genotype 1a

Patient characterization	Recommended	Duration (wk)	Scientific evidence	Real-world evidence
Genotype 1a naive noncirrhotic	SOF + LDV	12	ION-1
	SOF + LDV (CV < 6 × 10⁶ UI/mL)	8	ION-3
	OBV + PTVR + DSV + RBV	12	SAPHIRE I PEARL
	SOF + SIM	12	COSMOS	TARGET TRIO
	SOF + DCV	12
	SOF + PEG + RBV	12	NEUTRINO
Genotype 1anaive cirrhotic	SOF + LDV	12	ION-1
	OBV + PTVR + DSV + RBV	12	TURQUOISE-II PEARL
	SOF + SIM	12	COSMOS
	SOF + DCV	12
	SOF + PEG + RBV	12	NEUTRINO
Genotype 1a retretated noncirrhotic	SOF + LDV	12	ION-2
	OBV + PTVR + DSV + RBV	12	SAPHIRE-II
	SOF + SIM	12	COSMOS
	SOF + DCV	12/24
Genotipo 1a retreated cirrhotic	SOF + LDV + RBV	12	ION-2
	SOF + LDV	24	ION-2
	OBV + PTVR + DSV + RBV	12/24	TURQUOISE-II PEARL
	SOF + SIM	12	COSMOS
	SOF + DVC	24

SOF: Sofosbuvir; LDV: Ledipasvir.

Citation: González-Grande R, Jiménez-Pérez M, González Arjona C, Mostazo Torres J. New approaches in the treatment of hepatitis C. World J Gastroenterol 2016; 22(4): 1421-1432
URL: https://www.wjgnet.com/1007-9327/full/v22/i4/1421.htm
DOI: https://dx.doi.org/10.3748/wjg.v22.i4.1421